BRPI0618094A8 - Método para preparar um produto de cultura de célula - Google Patents

Método para preparar um produto de cultura de célula

Info

Publication number
BRPI0618094A8
BRPI0618094A8 BRPI0618094A BRPI0618094A BRPI0618094A8 BR PI0618094 A8 BRPI0618094 A8 BR PI0618094A8 BR PI0618094 A BRPI0618094 A BR PI0618094A BR PI0618094 A BRPI0618094 A BR PI0618094A BR PI0618094 A8 BRPI0618094 A8 BR PI0618094A8
Authority
BR
Brazil
Prior art keywords
cell culture
preparing
residual dna
dna
treatment
Prior art date
Application number
BRPI0618094A
Other languages
English (en)
Inventor
Gregersen Jens-Peter
Kost Holger
Original Assignee
Novartis Ag
Novartis Vaccines And Diagnostics Gmbh & Co Kg
Novartis Vaccines & Diagnostics Gmbh
Seqirus Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37969762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0618094(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Novartis Vaccines And Diagnostics Gmbh & Co Kg, Novartis Vaccines & Diagnostics Gmbh, Seqirus Uk Ltd filed Critical Novartis Ag
Publication of BRPI0618094A2 publication Critical patent/BRPI0618094A2/pt
Publication of BRPI0618094A8 publication Critical patent/BRPI0618094A8/pt
Publication of BRPI0618094B1 publication Critical patent/BRPI0618094B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

VACINAS VIRAIS DERIVADAS DE CÉLULAS COM NÍVEIS BAIXOS DE DNA RESIDUAL DE CÉLULA A presente invenção se refere aos produtos de vacina para o tratamento ou prevenção das infecções virais. São providos adicionalmente métodos para redução dos contaminantes associados à preparação das vacinas de culturais. O DNA residual da cultura de célula funcional é degradado por tratamento com um agente alquilante de DNA, tal como (Beta)-propiolactona (BPL), pelo que provendo uma vacina compreendendo proteínas imunogênicas derivados de um vírus propagado na cultura de célula, substancialmente isenta de DNA residual de cultura de célula funcional.
BRPI0618094-9A 2005-11-01 2006-11-01 Método para preparar um produto de cultura de célula BRPI0618094B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73278605P 2005-11-01 2005-11-01
US60/732.786 2005-11-01
PCT/IB2006/003880 WO2007052163A2 (en) 2005-11-01 2006-11-01 Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment

Publications (3)

Publication Number Publication Date
BRPI0618094A2 BRPI0618094A2 (pt) 2011-08-16
BRPI0618094A8 true BRPI0618094A8 (pt) 2017-08-22
BRPI0618094B1 BRPI0618094B1 (pt) 2023-07-11

Family

ID=

Also Published As

Publication number Publication date
JP2016185988A (ja) 2016-10-27
WO2007052163A2 (en) 2007-05-10
US11466257B2 (en) 2022-10-11
CN101365480A (zh) 2009-02-11
SI1951296T2 (sl) 2014-09-30
JP2020023557A (ja) 2020-02-13
ES2525518T3 (es) 2014-12-26
PL1951296T5 (pl) 2015-06-30
US20200377864A1 (en) 2020-12-03
PT2301572E (pt) 2014-12-22
NZ567817A (en) 2012-01-12
EA014062B1 (ru) 2010-08-30
ATE494906T1 (de) 2011-01-15
EP1951296B2 (en) 2014-07-23
KR20080081254A (ko) 2008-09-09
US20090304729A1 (en) 2009-12-10
PL1951296T3 (pl) 2011-09-30
HK1129837A1 (en) 2009-12-11
EA200801221A1 (ru) 2008-10-30
JP2009513694A (ja) 2009-04-02
HK1207828A1 (en) 2016-02-12
EP2842572A1 (en) 2015-03-04
SI1951296T1 (sl) 2011-04-29
JP2011256209A (ja) 2011-12-22
CY1111378T1 (el) 2015-08-05
CN104474543A (zh) 2015-04-01
ES2359214T3 (es) 2011-05-19
EP1951296B1 (en) 2011-01-12
CA2627971A1 (en) 2007-05-10
ES2359214T5 (es) 2014-10-08
EP1951296A2 (en) 2008-08-06
EP2301572A1 (en) 2011-03-30
US10655108B2 (en) 2020-05-19
AU2006310171B2 (en) 2011-02-17
AU2011201968B2 (en) 2014-08-28
BRPI0618094A2 (pt) 2011-08-16
AU2006310171A1 (en) 2007-05-10
WO2007052163A3 (en) 2007-09-07
CN101365480B (zh) 2014-11-05
JP2014198726A (ja) 2014-10-23
JP7049761B2 (ja) 2022-04-07
EP2301572B1 (en) 2014-09-10
PL2301572T3 (pl) 2015-02-27
AU2011201968A1 (en) 2011-05-19
DK1951296T4 (da) 2014-09-01
DK1951296T3 (da) 2011-03-28
DE602006019629D1 (de) 2011-02-24
JP6639077B2 (ja) 2020-02-05
JP5602366B2 (ja) 2014-10-08

Similar Documents

Publication Publication Date Title
HK1207828A1 (en) Cell-derived viral vaccines with low levels of residual cell dna dna
BR112012033767A2 (pt) processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina.
BR112013031021A2 (pt) composições e métodos para a inibição da expressão de gene do vírus da hepatite b'
BR112018009032A8 (pt) vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração
AR090470A1 (es) Vacuna contra el virus sincicial respiratorio (rsv)
BR112014004860A2 (pt) composições de anticorpo contra vírus da influenza
BR112013011194A2 (pt) partículas de glicoproteína semelhantes a vírus (vlps) da raiva.
MX2016004063A (es) Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta.
MX2013001613A (es) Métodos y composiciones para prevenir una afección.
BR112013030150A2 (pt) proteína l1 hpv33 truncada ou variante da mesma, ácido nucléico isolado, vetor, célula hospedeira, partícula do tipo viral hpv33, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv33 truncada, método para preparar a partícula do tipo viral hpv33, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada pela infecção de hpv e uso da proteína l1 hpv33 truncada ou variante da mesma
BR112018017307A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus
BR112013032251A2 (pt) composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
AR061894A1 (es) Vacunas para malaria
AR044696A1 (es) Composicion de vacunas
BR112012033457A2 (pt) formulações de anticorpo.
BR112015017966A2 (pt) composições imunogênicas compreendendo vírus silificado e métodos de uso
BR112015000585A2 (pt) cepas mutantes de mycoplasma hyopneumoniae
BR112014011345A2 (pt) partículas tipo vírus da influenza (vlps) compreendendo nicotiana tabacum produzida por hemaglutinina
BR112014017141A2 (pt) método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada
AU2017261706A1 (en) Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
BR112013006515A2 (pt) vacina de combinação, e, método para a fabricação de uma vacina de combinação
AR094810A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
BR112012015449A2 (pt) suspensão de monoidrato de calcipotriol, monoidrato de calcipotriol, processo para preparar nanocristais de monoidrato de calcipotriol, e, composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH (DE)

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B25A Requested transfer of rights approved

Owner name: SEQIRUS UK LIMITED (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/11/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.